Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead …Update-2
Update-2 Flashback from 1/19 and 2018 Performance. Big winner in 2018 was MRK up 33% to $76.41 but 2018 was a bad year with the XBI down 15% to $71.75. But Regeneron was a bargain on 1/19 at $373. Update-1 6/27...A bad day for Biotech but a nice rally day for Tech Most biotech shares were weak...
Biotech and Healthcare Stocks Lagging
Healthcare Stocks Lag but Trading Action is Picking up in Biotech Large Cap Biopharma are core holdings: ABBV, LLY, MRK, REGN, VRTX etc. Healthcare is a laggard with XLV down YTD but UNH is still a core position. Lack of Momentum in SMID caps-XBI is still the key indicator. Not much happened...
Macro Muddle Coming Up as Market Exceeds Expectations, Small Caps Gain Ground…Update-2
Update-2 6/18...11 a EDT, Medtech Rally: FSMEX , IHI, ABT, BSX etc. Update-1 2P EDT 6/14...FED day brings volatility and easing of momentum. Don't fight the tape with small caps weak. XBI is down 2%, Russell 2000 is down 1.65%. We started selling and rebalancing stocks in our Life Science...
Market Mixes it Up With a Broad Rally…Update-2 6/7/23
FOCUS on SMID biotech stocks. Update-2 ..more rotation out of tech and large cap biopharma and healthcare (UNH, XLV still weak) into value and cyclicals; energy very strong we'll see. We still prefer SMID in biotech per our Life Science Portfolio. Today XBI was flat at $88 but good gains in EVH...
Rotation Out of Healthcare and Biotech Stocks: Age of Disruption? Update-1 Large Cap Biopharma
Update -1 3/31 2P EDT. With momentum easing in Chip and IT trades this can be a good entry point for large cap biopharma stocks ahead of ASCO June 2: GILD, MRK so stay tuned. Also for value "bottom fishers" Pfizer offers a good yield of 4.4% with a FWD PE about 10 and a strong balance sheet....